Medical Oncology and Hematology,DIANE DUYEN NGUYEN, D.O.

Dr. Nguyen is dual board-certified in Medical Oncology and Hematology. She completed Hematology/Oncology Fellowship training at the University of Texas Health Sciences Center in San Antonio and Internal Medicine Residency at Saint Louis University, School of Medicine in St. Louis, Missouri. She obtained a medical degree from West Virginia School of Osteopathic Medicine in Lewisburg, WV and achieved an undergraduate degree in Biology Science with Summa cum laude at Christian Brothers University in Memphis, TN.

Dr. Nguyen is currently a Medical Oncologist/Hematologist at University Cancer & Diagnostic Centers. Dr. Nguyen was an Assistant Professor of Medicine in the Division of Hematology/Oncology at University of Texas Medical Branch (UTMB) in Galveston. She joined UTMB as a faculty in the Department of Internal Medicine. Dr. Nguyen also served as an Assistant Professor of Medicine and Associate Program Director of Hematology/Oncology Fellowship at Texas Tech University Health Sciences Center in Lubbock, Texas. She was an Associate Director of Breast Cancer Program and a Leading Core Oncology Faculty of Multidisciplinary Breast Cancer and Head & Neck Cancer Clinics at South West Cancer Treatment & Research Center and University Medical Center in Lubbock. Prior to her academic career, Dr. Nguyen was in private practice with Tennessee Oncology group located in Nashville, TN. She is an active member of American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), Texas Medical Association (TMA), and Vietnamese American Medical Association (VAMA).

Dr. Nguyen has great clinical and research interests in the diagnosis and treatment of Breast, Ovarian, Gastrointestinal, Lung, Head & Neck Cancers as well as Lymphoma, Myeloma, and Leukemia. She’s also interested in treatments of other Malignant and Benign Hematological disorders. She has more than 10 years of clinical and research experiences in Medical Oncology and Hematology. She has participated in both clinical trials and translational research in breast and ovarian cancers as well as other solid tumors and hematologic malignancies. She has published papers in the field of Immunotherapy Oncology for Breast, Ovarian, Lung, Head & Neck Cancers, and Myeloma as well as other malignancies.


­­­­­­­­­­­­­­­­ Publications

The cancer-testis antigen, sperm protein 17, a new biomarker and immunological target in head and neck squamous cell carcinoma.
Schutt CA, Mirandola L, Figueroa JA, Nguyen DD, Cordero J, Bumm K, Judson BL, Chiriva-Internati M.
Oncotarget. 2017 Oct 31;8(59):100280-100287. doi: 10.18632/oncotarget.22213. eCollection 2017 Nov 21.
Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer.
Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, Grizzi F, Cobos E, Figueroa JA, Chiriva-Internati M.
Gynecol Oncol. 2014 Dec;135(3):573-9. doi: 10.1016/j.ygyno.2014.09.021. Epub 2014 Oct 6.
Mast cells and the liver aging process.
Grizzi F, Di Caro G, Laghi L, Hermonat P, Mazzola P, Nguyen DD, Radhi S, Figueroa JA, Cobos E, Annoni G, Chiriva-Internati M.
Immun Ageing. 2013 Mar 7;10(1):9. doi: 10.1186/1742-4933-10-9.
Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.
Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C, Grizzi F, Patrinicola F, Kast WM, Nguyen DD, Rahman RL, Daver N, Ruvolo P, Post SM, Bresalier RS, Chiriva-Internati M.
Oncotarget. 2017 Aug 10;8(43):74378-74390. doi: 10.18632/oncotarget.20102. eCollection 2017 Sep 26.
The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review.
Cobos C, Figueroa JA, Mirandola L, Colombo M, Summers G, Figueroa A, Aulakh A, Konala V, Verma R, Riaz J, Wade R, Saadeh C, Rahman RL, Pandey A, Radhi S, Nguyen DD, Jenkins M, Chiriva-Internati M, Cobos E.
Int Rev Immunol. 2014 Oct;33(5):383-401. doi: 10.3109/08830185.2014.911857. Epub 2014 May 8. Review.

Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability.
Pandey A, Kurup A, Shrivastava A, Radhi S, Nguyen DD, Arentz C, D’Chuna N, Hardwick F, D’Souza MJ, Jenkins M, Grizzi F, Kast WM, Cobos E, Rahman R, Chiriva-Internati M, Chiaramonte R, Platonova N.
Int Rev Immunol. 2012 Oct;31(5):302-20. doi: 10.3109/08830185.2012.723511. Review.

Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2.
Dean M, Boland J, Yeager M, Im KM, Garland L, Rodriguez-Herrera M, Perez M, Mitchell J, Roberson D, Jones K, Lee HJ, Eggebeen R, Sawitzke J, Bass S, Zhang X, Robles V, Hollis C, Barajas C, Rath E, Arentz C, Figueroa JA, Nguyen DD, Nahleh Z.
Gigascience. 2015 Nov 4;4:50. doi: 10.1186/s13742-015-0088-z. eCollection 2015.

Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer?
Mirandola L, Nguyen DD, Rahman RL, Grizzi F, Yuefei Y, Figueroa JA, Jenkins MR, Cobos E, Chiriva-Internati M.
Int Rev Immunol. 2014 Oct;33(5):417-27. doi: 10.3109/08830185.2014.911855. Epub 2014 May 6. Review.

Application of vitamin D and derivatives in hematological malignancies.
Kim M, Mirandola L, Pandey A, Nguyen DD, Jenkins MR, Turcel M, Cobos E, Chiriva-Internati M.
Cancer Lett. 2012 Jun 1;319(1):8-22. doi: 10.1016/j.canlet.2011.10.026. Epub 2011 Dec 19. Review.